Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Wolfe Research Upgrades Grainger (GWW) to Peerperform (correction)
• Amphenol (APH) PT Raised to $185 at BofA Securities
• Bandwidth Inc. (BAND) PT Raised to $85 at B.Riley